NEW YORK (GenomeWeb News) – Life Technologies today announced a commercialization deal covering three stem cell technologies from Cellular Dynamics International for the consistent development and growth of human iPS cells for research and bioproduction.

Life Tech will commercialize CDI's Essential 8 Medium, Vitronectin, and Episomal iPSC Reprogramming Vectors, which together address several challenges associated with developing relevant cells, the Carlsbad, Calif.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."